Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.75 |
| ▸ | MAPT | P10636 | 4/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | CTSL | P07711 | 4/20 | 0.72 |
| ▸ | CTSS | P25774 | 1/20 | 0.72 |
| ▸ | CTSK | P43235 | 1/20 | 0.72 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | ACHE | P22303 | 2/20 | 0.57 |
| ▸ | BCHE | P06276 | 1/20 | 0.57 |
| ▸ | CCKBR | P32239 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | ACE | P12821 | 1/20 | 0.56 |
| ▸ | TACR3 | P29371 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8482130 | 0.90 | CTSL (0.73) | TACR1MAPTLMNACTSLCTSS | |
| SCHEMBL7745574 | 0.89 | CTSL (0.72) | TACR1MAPTLMNACTSLCTSS | |
| SCHEMBL9834534 | 0.88 | CTSL (0.80) | TACR1MAPTLMNACTSLCTSS | |
| Water SCHEMBL27383247 | 0.86 | MAPT (0.76) | TACR1MAPTLMNACTSLCTSS | |
| SCHEMBL29419170 | 0.86 | CTSL (0.77) | TACR1MAPTCTSLCTSSCTSK | |
| SCHEMBL21286953 | 0.86 | CTSL (0.77) | TACR1MAPTCTSLCTSSCTSK | |
| SCHEMBL21269082 | 0.86 | CTSL (0.77) | TACR1MAPTCTSLCTSSCTSK | |
| SCHEMBL17807348 | 0.86 | CTSL (0.80) | TACR1MAPTCTSLCTSSCTSK | |
| SCHEMBL9263952 | 0.86 | TACR1 (1.00) | TACR1MAPTLMNACTSLCTSS | |
| SCHEMBL27839975 | 0.85 | CTSL (0.69) | TACR1MAPTLMNACTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6869957-B1 | Non-peptide tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 2005-03-22 | — | — | US | disclosed |
| US-6727255-B1 | BRAIN, NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDERS | ELI LILLY AND COMPANY | 2004-04-27 | — | — | US | disclosed |
| EP-0699665-B1 | Imidazoline derivatives, their preparation and their use as tachykinin receptor antagonists | LILLY CO ELI (US) | 2003-03-05 | — | — | EP | disclosed |
| EP-0729468-B1 | NON-PEPTIDE TACHYKININ RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2003-01-15 | — | — | EP | disclosed |
| US-6403577-B1 | Hexamethyleneiminyl tachykinin receptor antagonists | ELI LILLY AND COMPANY | 2002-06-11 | — | — | US | disclosed |
| US-6303610-B1 | ADMINISTERING TRYPTOPHAN DERIVATIVES AS NEUTROPHIL MEDIATED OXIDANT PRODUCTION FOR THERAPY OF NEUTROPHIL ASSOCIATED DISEASES AND DISORDERS | ELI LILLY AND COMPANY | 2001-10-16 | — | — | US | disclosed |
| US-6175013-B1 | 1-(2-METHOXYBENZYL)-2-((4-PHENYL-1-PIPERAZINYL)METHYL)-4-(1H -INDOL-3-YLMETHYL)-2-IMIDAZOLINE, FOR EXAMPLE; ADMINSTERING TO TREAT ANXIETY, DEPRESSION, PSYCHOSIS, AND SCHIZOPHRENIA | ELI LILLY AND COMPANY | 2001-01-16 | — | — | US | disclosed |
| EP-0994712-A1 | INHIBITORS OF NEUTROPHIL MEDIATED OXIDANT PRODUCTION | ELI LILLY AND COMPANY (US) | 2000-04-26 | — | — | EP | disclosed |
| WO-1999002163-A1 | INHIBITORS OF NEUTROPHIL MEDIATED OXIDANT PRODUCTION | ELI LILLY AND COMPANY (US) | 1999-01-21 | — | — | WO | disclosed |
| US-5792760-A | USEFUL IN TREATMENT OF PSYCHOLOGICAL AND CENTRAL NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1998-08-11 | — | — | US | disclosed |
| US-5670499-A | PHYSIOLOGICAL DISORDERS, GASTROINTESTINAL DISORDERS, ANTIINFLAMMATORY AGENTS | ELI LILLY AND COMPANY (US) | 1997-09-23 | — | — | US | disclosed |
| EP-0761220-A1 | 2-Acylaminopropanamides as growth hormone secretagogues | ELI LILLY AND COMPANY (US) | 1997-03-12 | — | — | EP | disclosed |
| EP-0761219-A1 | 2-Acylaminopropanamines as growth hormone secretagogues | ELI LILLY AND COMPANY (US) | 1997-03-12 | — | — | EP | disclosed |
| WO-1997007117-A1 | 2-ACYLAMINOPROPANAMINES AS GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 1997-02-27 | — | — | WO | disclosed |
| WO-1997006803-A1 | 2-ACYLAMINOPROPANAMIDES AS GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 1997-02-27 | — | — | WO | disclosed |
| US-5565568-A | USEFUL IN TREATMENT OR PREVENTION OF A PHYSIOLOGICAL DISORDER ASSOCIATED WITH AN EXCESS OF TACHYKININS | ELI LILLY AND COMPANY (US) | 1996-10-15 | — | — | US | disclosed |
| EP-0729468-A1 | NON-PEPTIDE TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-09-04 | — | — | EP | disclosed |
| EP-0729468-A4 | NON-PEPTIDE TACHYKININ RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1996-07-12 | — | — | EP | disclosed |
| EP-0699665-A1 | Imidazoline derivatives, their preparation and their use as tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 1996-03-06 | — | — | EP | disclosed |
| WO-1995014017-A1 | NON-PEPTIDE TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1995-05-26 | — | — | WO | disclosed |